DCM
TPTX

DAFNA Capital Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

DAFNA Capital Management’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-48,452
Closed -$3.65M – 95
2022
Q2 		$3.65M Sell
48,452
-11,000
-19% -$489K 0.99% 32
2022
Q1 		$1.6M Buy
59,452
+13,000
+28% +$437K 0.42% 60
2021
Q4 		$2.22M Buy
46,452
+4,500
+11% +$201K 0.56% 40
2021
Q3 		$2.79M Sell
41,952
-5,900
-12% -$420K 0.74% 36
2021
Q2 		$3.73M Buy
47,852
+37,343
+355% +$2.76M 0.78% 32
2021
Q1 		$994K Buy
+10,509
New +$1.25M 0.24% 71
2020
Q3 		– Sell
-23,210
Closed -$1.5M – 96
2020
Q2 		$1.5M Sell
23,210
-23,698
-51% -$1.37M 0.43% 45
2020
Q1 		$2.1M Buy
46,908
+16,500
+54% +$876K 0.87% 33
2019
Q4 		$1.89M Sell
30,408
-16,900
-36% -$804K 0.65% 34
2019
Q3 		$1.78M Buy
+47,308
New +$2.06M 0.67% 39

DAFNA Capital Management's TPTX Position: Q3 2022 in Review

DAFNA Capital Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 48,452 shares — an estimated $3.65M sold.

DAFNA Capital Management first reported a position in TPTX in Q3 2019 and held it in 10 quarters. The position peaked at $3.73M in Q2 2021. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • DAFNA Capital Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • DAFNA Capital Management sold 48,452 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $3.65M.
  • DAFNA Capital Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q3 2019 and held it in 10 quarters.
  • DAFNA Capital Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $3.73M in Q2 2021.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on DAFNA Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.